In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...

In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 ...

The FDA granted priority review designation to J&J’s biologics license application (BLA) seeking approval of nipocalimab for antibody-positive patients with gMG, a rare, autoantibody-driven ...

We recently compiled a list of the 10 Best High-Yield Dividend Stocks To Invest In. In this article, we are going to take a ...

Citi analyst Geoff Meacham maintained a Hold rating on Pfizer (PFE – Research Report) today. The company’s shares closed yesterday at $26.80. Discover outperforming stocks and invest smarter ...

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The company’s shares closed today at $26.41. Discover ...

FDA Requires New Warning on PFE & GSK’s RSV Vaccines’ Label ... Both Abrysvo and Arexvy were approved in May 2023. The NYSE ARCA Pharmaceutical Index rose 0.8% in the past five trading sessions.

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other pharma ...

Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy ...